Extracellular Vesicles for Ocular Inflammation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chemical injuries of the eye, particularly alkali burns and ocular graft-versus-host disease (GVHD), lack effective pharmacologic options, and existing therapies for dry eye disease are inadequate, with a need for innovative approaches to enhance recovery, minimize collagen breakdown, and control inflammation.
Innovation Solution
The use of extracellular vesicles, specifically exosomes derived from cardiosphere-derived cells (CDCs), which are administered topically or via subconjunctival injection to treat chemical injuries of the eye, including alkali burns, ocular GVHD, and dry eye disease, by promoting regeneration and modulating inflammatory pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for chemical injuries of the eye, then standard care is provided, but effective pharmacologic options are lacking and treatment outcomes are inadequate
Solution Approach 1:
The patent changes the fundamental parameter of treatment modality by introducing extracellular vesicles (EVs) as a novel pharmacologic agent. EVs are administered topically or via subconjunctival injection, representing a new delivery parameter and mechanism of action that differs from conventional treatments. This parameter change enables effective treatment of chemical injuries where standard therapies have failed.
Solution Approach 2:
Extracellular vesicles serve as an intermediary substance that mediates the therapeutic effect between the administered treatment and the injured ocular tissues. The EVs carry bioactive molecules that modulate inflammation and promote regeneration, acting as a bridge that delivers therapeutic effects without the direct toxicity or limitations of conventional pharmacologic agents.
2Object-affected harmful factors
If aggressive treatment is applied to chemical injuries, then inflammation control is attempted, but collagen breakdown increases and recovery is hindered
Solution Approach 1:
The patent converts the harmful inflammatory response into a beneficial regenerative process. Extracellular vesicles modulate the inflammatory cascade to resolve inflammation while simultaneously activating tissue repair mechanisms. This transforms the normally harmful inflammatory state into a controlled process that promotes collagen synthesis and tissue regeneration rather than breakdown.
Solution Approach 2:
The treatment changes the parameter of tissue response by shifting from a catabolic state (collagen breakdown) to an anabolic state (collagen synthesis). EVs alter the biochemical parameters of the injured tissue environment, promoting conditions favorable for collagen production and tissue repair while suppressing excessive inflammation that would otherwise lead to further damage.
3Reliability
If existing therapies for dry eye disease are used, then standard management is provided, but treatment adequacy is insufficient and recovery is limited
Solution Approach 1:
Extracellular vesicles act as an intermediary therapeutic agent that addresses the underlying pathophysiology of dry eye disease. The EVs deliver bioactive molecules that restore normal ocular surface function, promote epithelial healing, and modulate inflammation in a way that conventional therapies cannot achieve, thereby enhancing recovery productivity.
Solution Approach 2:
The treatment changes key parameters of ocular surface health including epithelial integrity, tear film stability, and inflammatory status. By administering EVs, the patent alters the physiological parameters of the ocular surface system, enabling recovery and function that exceeds the capabilities of existing dry eye therapies.
Data Source
AI summary
The present invention relates to a method of treating a chemical injury of the eye, in particular alkali burn of the cornea, as well as ocular GVHD and similar inflammatory ocular conditions, with extracellular vesicles, in particular exosomes obtained from human cardiospheres or cardiosphere-derived cells. The present invention also provides a formulation comprising extracellular vesicles, in particular exosomes obtained from human cardiospheres or cardiosphere-derived cells, for subconjunctival or topical administration to the eye in the treatment of a chemical injury of the eye, in particular alkali burn of the cornea, as well as ocular GVHD and similar inflammatory ocular conditions.